. Author manuscript; available in PMC: 2012 Apr 9.

Published in final edited form as: Biol Blood Marrow Transplant. 2008 Sep;14(9):993–1003. doi: 10.1016/j.bbmt.2008.06.009

Table 3.

Multivariate analysis comparing transplant outcomes between HLA-identical patients who received Fludarabine + Busulfan + Thymoglobulin as conditioning (Cases) with HLA-identical patients who received Busulfan + Cyclophosphamide for their conditioning (Controls), after transplantation.

Outcome of interest	N eval	Relative Risk (95% Confidence Interval)	P - value
Acute GVHD^b
Main effect:
Controls	215	1.00^a
Cases	120	0.36 (0.21–0.63)	0.0003
Chronic GVHD^b
Main effect:
Controls	213	1.00^a
Cases	120	1.28 (0.83–1.98)	0.2607
Treatment related mortality^b
Main effect:
Controls	215	1.00^a
Cases	120	0.322 (0.16 – 0.64)	0.0013
Relapse/progression^b
Main effect:
Controls	215	1.00^a
Cases	120	1.91 (1.14–3.19)	0.0138
Treatment failure^b
Main effect:
Controls	215	1.00^a
Cases	120	0.90 (0.62 – 1.31)	0.5901
Overall survival^b
Main effect:
Controls	215	1.00^a
Cases	120	0.644 (0.43–0.96)	0.0298

Abbreviations: GVHD= graft-versus-host disease.

Reference group.

No other covariates were significant.